vs
Ginkgo Bioworks Holdings, Inc.（DNA）与LandBridge Co LLC（LB）财务数据对比。点击上方公司名可切换其他公司
LandBridge Co LLC的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.5倍（$51.0M vs $33.4M），LandBridge Co LLC同比增速更快（16.0% vs -23.8%），LandBridge Co LLC自由现金流更多（$40.9M vs $-47.7M），过去两年LandBridge Co LLC的营收复合增速更高（40.2% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
DNA vs LB — 直观对比
营收规模更大
LB
是对方的1.5倍
$33.4M
营收增速更快
LB
高出39.9%
-23.8%
自由现金流更多
LB
多$88.6M
$-47.7M
两年增速更快
LB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $51.0M |
| 净利润 | — | $17.9M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 57.2% |
| 净利率 | — | 35.0% |
| 营收同比 | -23.8% | 16.0% |
| 净利润同比 | — | 15.6% |
| 每股收益（稀释后） | $-1.41 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNALB
| Q1 26 | — | $51.0M | ||
| Q4 25 | $33.4M | $56.8M | ||
| Q3 25 | $38.8M | $50.8M | ||
| Q2 25 | $49.6M | $47.5M | ||
| Q1 25 | $48.3M | $44.0M | ||
| Q4 24 | $43.8M | $36.5M | ||
| Q3 24 | $89.0M | $28.5M | ||
| Q2 24 | $56.2M | $26.0M |
净利润DNALB
| Q1 26 | — | $17.9M | ||
| Q4 25 | — | $8.1M | ||
| Q3 25 | $-80.8M | $8.1M | ||
| Q2 25 | $-60.3M | $7.5M | ||
| Q1 25 | $-91.0M | $6.5M | ||
| Q4 24 | — | $49.3M | ||
| Q3 24 | $-56.4M | $2.7M | ||
| Q2 24 | $-217.2M | $-57.7M |
营业利润率DNALB
| Q1 26 | — | 57.2% | ||
| Q4 25 | -211.9% | 60.0% | ||
| Q3 25 | -231.8% | 60.8% | ||
| Q2 25 | -132.1% | 60.0% | ||
| Q1 25 | -184.1% | 57.0% | ||
| Q4 24 | -236.3% | 49.4% | ||
| Q3 24 | -62.0% | 11.2% | ||
| Q2 24 | -396.7% | -197.4% |
净利率DNALB
| Q1 26 | — | 35.0% | ||
| Q4 25 | — | 14.2% | ||
| Q3 25 | -207.9% | 15.9% | ||
| Q2 25 | -121.6% | 15.8% | ||
| Q1 25 | -188.2% | 14.7% | ||
| Q4 24 | — | 135.2% | ||
| Q3 24 | -63.3% | 9.3% | ||
| Q2 24 | -386.4% | -222.1% |
每股收益（稀释后）DNALB
| Q1 26 | — | — | ||
| Q4 25 | $-1.41 | $0.24 | ||
| Q3 25 | $-1.45 | $0.26 | ||
| Q2 25 | $-1.10 | $0.24 | ||
| Q1 25 | $-1.68 | $0.20 | ||
| Q4 24 | $-1.91 | — | ||
| Q3 24 | $-1.08 | $-0.04 | ||
| Q2 24 | $-4.23 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $29.7M |
| 总债务越低越好 | — | $433.0K |
| 股东权益账面价值 | $508.6M | — |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNALB
| Q1 26 | — | $29.7M | ||
| Q4 25 | $422.6M | $30.7M | ||
| Q3 25 | $495.5M | $28.3M | ||
| Q2 25 | $559.4M | $20.3M | ||
| Q1 25 | $325.3M | $14.9M | ||
| Q4 24 | $561.6M | $37.0M | ||
| Q3 24 | $616.2M | $14.4M | ||
| Q2 24 | $730.4M | $24.6M |
总债务DNALB
| Q1 26 | — | $433.0K | ||
| Q4 25 | — | $570.7M | ||
| Q3 25 | — | $366.1M | ||
| Q2 25 | — | $370.9M | ||
| Q1 25 | — | $375.5M | ||
| Q4 24 | — | $385.5M | ||
| Q3 24 | — | $242.4M | ||
| Q2 24 | — | $360.8M |
股东权益DNALB
| Q1 26 | — | — | ||
| Q4 25 | $508.6M | $340.3M | ||
| Q3 25 | $559.8M | $272.0M | ||
| Q2 25 | $613.0M | $266.4M | ||
| Q1 25 | $647.4M | $217.0M | ||
| Q4 24 | $716.1M | $211.8M | ||
| Q3 24 | $797.9M | $97.2M | ||
| Q2 24 | $833.1M | $296.4M |
总资产DNALB
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.4B | $1.0B | ||
| Q3 24 | $1.5B | $689.9M | ||
| Q2 24 | $1.6B | $710.5M |
负债/权益比DNALB
| Q1 26 | — | — | ||
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.73× | ||
| Q4 24 | — | 1.82× | ||
| Q3 24 | — | 2.49× | ||
| Q2 24 | — | 1.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $41.1M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $40.9M |
| 自由现金流率自由现金流/营收 | -142.8% | 80.3% |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 2.30× |
| 过去12个月自由现金流最近4个季度 | — | $232.8M |
8季度趋势，按日历期对齐
经营现金流DNALB
| Q1 26 | — | $41.1M | ||
| Q4 25 | $-47.7M | $126.3M | ||
| Q3 25 | $-31.6M | $34.9M | ||
| Q2 25 | $-40.3M | $37.3M | ||
| Q1 25 | $-51.5M | $15.9M | ||
| Q4 24 | $-42.4M | $67.6M | ||
| Q3 24 | $-103.5M | $7.5M | ||
| Q2 24 | $-84.4M | $16.0M |
自由现金流DNALB
| Q1 26 | — | $40.9M | ||
| Q4 25 | $-47.7M | $122.0M | ||
| Q3 25 | — | $33.7M | ||
| Q2 25 | $-40.3M | $36.1M | ||
| Q1 25 | $-59.1M | $15.8M | ||
| Q4 24 | $-56.1M | $66.7M | ||
| Q3 24 | $-118.6M | $7.1M | ||
| Q2 24 | $-111.4M | $15.7M |
自由现金流率DNALB
| Q1 26 | — | 80.3% | ||
| Q4 25 | -142.8% | 214.9% | ||
| Q3 25 | — | 66.3% | ||
| Q2 25 | -81.2% | 75.9% | ||
| Q1 25 | -122.4% | 36.0% | ||
| Q4 24 | -128.0% | 182.6% | ||
| Q3 24 | -133.2% | 25.1% | ||
| Q2 24 | -198.2% | 60.4% |
资本支出强度DNALB
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 15.8% | 0.2% | ||
| Q4 24 | 31.3% | 2.7% | ||
| Q3 24 | 16.9% | 1.1% | ||
| Q2 24 | 48.1% | 1.4% |
现金转化率DNALB
| Q1 26 | — | 2.30× | ||
| Q4 25 | — | 15.68× | ||
| Q3 25 | — | 4.31× | ||
| Q2 25 | — | 4.98× | ||
| Q1 25 | — | 2.46× | ||
| Q4 24 | — | 1.37× | ||
| Q3 24 | — | 2.80× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
LB
| Other | $14.2M | 28% |
| Easements and other surface-related revenues | $11.6M | 23% |
| Surface use royalties - related party | $11.0M | 22% |
| Resource sales | $5.2M | 10% |
| Resource royalties | $4.3M | 8% |
| Easements and other surface-related revenues - related party | $3.2M | 6% |
| Resource royalties - related party | $1.3M | 2% |
| Resource sales - related party | $205.0K | 0% |
